UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study

Schizophrenia research, 2013-10, Vol.150 (1), p.281-288

2013

Volltextzugriff (PDF)

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

British journal of clinical pharmacology, 2012-04, Vol.73 (4), p.579-587

2012

Volltextzugriff (PDF)

SAFETY AND EFFECT ON ROD FUNCTION OF ACU-4429, A NOVEL SMALL-MOLECULE VISUAL CYCLE MODULATOR

Retina (Philadelphia, Pa.), 2012-01, Vol.32 (1), p.183-188

2012

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

Journal of clinical pharmacology, 2007-12, Vol.47 (12), p.1498-1507

2007

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

European journal of clinical pharmacology, 2012-12, Vol.68 (12), p.1595-1603

2012

Volltextzugriff (PDF)

Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers

Journal of clinical pharmacology, 2004-02, Vol.44 (2), p.179-187

2004

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2020-12, Vol.65 (1)

2020

Volltextzugriff (PDF)

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.761-769

2011

Volltextzugriff (PDF)

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

International journal of clinical pharmacology and therapeutics, 2012-02, Vol.50 (2), p.150-156

2012

Volltextzugriff (PDF)

Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate

Journal of clinical pharmacology, 2005-01, Vol.45 (1), p.89-93

2005

Volltextzugriff (PDF)

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

Clinical pharmacokinetics, 2008-01, Vol.47 (8), p.533-542

2008

Volltextzugriff (PDF)

Pharmacokinetics of aripiprazole and concomitant carbamazepine

Journal of clinical psychopharmacology, 2007-06, Vol.27 (3), p.279-283

2007

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

Clinical pharmacology in drug development, 2012-04, Vol.1 (2), p.67-75

2012

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

Kidney international, 2014-04, Vol.85 (4), p.953-961

2014

Volltextzugriff (PDF)

Cytomegalovirus Antibody Responses Associated With Increased Risk of Tuberculosis Disease in Ugandan Adults

The Journal of infectious diseases, 2020-03, Vol.221 (7), p.1127-1134

2020

Volltextzugriff (PDF)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.5976-5985

2016

Volltextzugriff (PDF)

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2022-02, Vol.66 (2), p.e0160821

2022

Volltextzugriff (PDF)

Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator

Retina (Philadelphia, Pa.), 2012-01, Vol.32 (1), p.183

2012

Volltextzugriff (PDF)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2020-12, Vol.65 (1)

2020

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia

Clinical pharmacology in drug development, 2022-02, Vol.11 (2), p.150-164

2022

Volltextzugriff (PDF)

Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers

Retina (Philadelphia, Pa.), 2014-03, Vol.34 (3), p.603-609

2014

Volltextzugriff (PDF)

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia

PharmacoEconomics, 2022-01, Vol.40 (1), p.121-131

2022

Volltextzugriff (PDF)

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

European journal of clinical pharmacology, 2012-02, Vol.68 (2), p.207-211

2012

Volltextzugriff (PDF)

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin

Clinical pharmacokinetics, 1999, Vol.37 Suppl 2 (Supplement 2), p.79-86

1999

Volltextzugriff (PDF)

Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole

Current medical research and opinion, 2013-10, Vol.29 (10), p.1241-1251

2013

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(41)
Dissertationen
(1)

Sprache

Englisch
(42)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

SAFETY AND EFFECT ON ROD FUNCTION OF ACU-4429, A NOVEL SMALL-MOLECULE VISUAL CYCLE MODULATOR

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

Pharmacokinetics of aripiprazole and concomitant carbamazepine

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

Cytomegalovirus Antibody Responses Associated With Increased Risk of Tuberculosis Disease in Ugandan Adults

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia

Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin

Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole

Suchergebnisse filtern